Archive for the ‘Activism’ Category

Efficacy of COVID Boosters Against Severe Illness & Death is a Wishful Myth

https://www.jpands.org/vol28no1/ophir.pdf

The Efficacy of COVID-19 Vaccine Boosters against Severe Illness and Deaths: Scientific Fact or Wishful Myth?

Yaakov Ophir, Ph.D. Yaffa Shir-Raz, Ph.D. Shay Zakov, Ph.D. Peter A. McCullough, M.D., M.P.H.

ABSTRACT

The medical narrative justifying the global vaccination campaign has changed throughout the coronavirus disease 2019 (COVID-19) crisis. While the primary narrative focused on the proclaimed excellent ability of the novel mRNA vaccines to prevent infections and (therefore) to attenuate the spread of the pandemic, policymakers today (March 2023) acknowledge the poor vaccine efficacy (VE) of contemporary booster doses against infections but insist that the boosters are still capable of providing long-term protection against severe illness and deaths (as if the two types of protection do not depend on each other). We examine the evidence behind this modified narrative through an in-depth evaluation of representative and high-profile data from: (1) the formal, phase 3 clinical trials by Pfizer and Moderna, which preceded the FDA’s emergency use authorization (EUA); (2) the observational studies from Israel (“the world’s lab,” as termed by Pfizer officials), which examined the efficacy of the fourth dose at about the time the FDA authorized this second booster; and (3) the publicly available, real-life dashboards of pandemic statistics.

This investigation encountered multiple methodological and representational constraints, including short, and sometimes arbitrary or uneven follow-up periods; uneven exclusion criteria and COVID-19 testing levels; selection biases; and selective report of results. But most importantly, the documented, conditional probability of death and severe illness (i.e., the percentage of severe illness and death cases among those infected with the virus) did not differ between the treatment and the control groups of the various clinical and observational efficacy studies. Altogether, the representative data examined in this article do not lend convincing support to the notion that the current booster doses offer protection against severe illness and deaths that extends significantly beyond their temporary and fragile protection against infections. Considering the already known poor efficacy against infections and transmission and the ever-growing concerns over serious, vaccine-associated adverse outcomes, the findings of this meticulous scientific investigation challenge the current (modified) narrative and serve as an urgent call for the medical community to reconsider the balance between the benefits and the risks of the newly developed COVID-19 vaccines. (See link for entire study)

_________________

**Comment**

Efficacy has been dealt with by experts many, many times over; however, the bought out media is simply not reporting on the way ‘the powers that be’ have manipulated, skewed, hidden, and outright lied about data.  It’s also important to remember that similarly to Lyme/MSIDS, the entire house of cards is built on false premises including:

  • they have never, to this day, created a successful”vaccine” for an upper respiratory disease
  • a “vaccine” isn’t needed for an illness which has a 99.991% recovery rate by doing nothing
  • the entire house of cards is based upon flawed testing making everything COVID when it could simply be the flu
  • this article points out that these injections lack a viable mechanism of action against COVID in the airways and that antibodies cannot prevent injection due to the fact COVID invades through the respiratory tract and that none of the “vaccine” trials gave any evidence that they prevent transmission.  Urging people to get these fast-tracked gene therapy injections to “protect others” has NO basis in fact
  • Despite forcing countries to put up sovereign assets including their bank reserves, military bases, and embassy buildings as collateral, these “vaccine” manufacturers ADMIT efficacy and risks are UNKNOWN
  • when absolute risk is taken into account, these injections are less than 1% effective
  • COVID “vaccine” manufacturers have unblinded their trials giving control groups the actual “vaccine,” making long-term efficacy and safety impossible to assess
  • Every clinical study and non-peer reviewed press release regarding efficacy needs to be revisited due to the sleight-of-statistical hand and the faulty PCR used in these studies.  Please remember that the CDC did not consider people “vaccinated” until up to five weeks after the initial dose – demonstrating brazen statistical manipulation to bury perception of adverse events and deaths
  • CDC data has shown that mass “vaccination” has had NO measurable impact on COVID mortality.
  • Thanks to a federal court order, the FDA has confirmed graphene is in the COVID shots. Spanish researchers have found that graphene makes up more than 99% of the injection
  • German researchers have found each and every vial to be contaminated with toxic ingredients
  • The COVID gene therapy injections have caused more reports of adverse reactions and death than any other vaccine in the history of VAERS

For more:

Category:

Activism, vaccines, Viruses

Pfizer May Be Taken to Court, The French Suffering Cardiac Events, But Biden Still Signs $5 Billion Deal With Big Pharma For More Shots

https://theprint.in/world/british-indian-medic-backs-legal-review-of-covid-vaccine-in-south-africa-high-court

British Indian medic backs legal review of COVID vaccine in South Africa High Court

 

London, Mar 29 (PTI) Leading UK-based Indian-origin consultant cardiologist Aseem Malhotra is among a group of international experts backing an approach to the High Court of South Africa, calling for an urgent judicial review of Pfizer’s mRNA COVID vaccine products which he fears may be “harmful”.

Lawyers representing the human rights group Freedom Alliance of South Africa (FASA) say the show cause notice was filed on Monday at the High Court of South Africa, Gauteng Division, Pretoria, along with real-world data analysis, which is claimed to show an association with increasing death from both COVID and non-COVID causes in the vaccinated compared to the unvaccinated.

FASA has approached the court to review and set aside the authorization of Pfizer’s vaccine products on the basis that the authorization was “unlawful”.

If successful, this could result in the removal of COVID mRNA vaccines from the South African market and also have global implications.

(See link for article)

Here’s Malhotra’s tweet on the statement.

______________

SUMMARY:

  • Malhotra states that the literature and the trial data shows unequivocally that for the majority of people, the Pfizer shot is more harmful than beneficial and should never have even been approved.
  • Malhotra states the injections should be halted pending a full investigation.
  • Dr Herman Edeling, neurosurgeon with over 40 years of experience, notes that the mRNA “vaccine” administered as Comirnaty in South Africa should “never have been branded as ‘safe’ and ‘effective’”.
  • The application calls on Pfizer to explain their conduct and calls on regulators and government to hold Pfizer accountable.
  • FASA hopes to announce a date of hearing soon.
  • Pfizer is predictably silent.

________________

https://petermcculloughmd.substack.com/p/hundreds-of-french-citizens-suffer

Hundreds of French Citizens Suffer Cardiac Events after Bivalent Boosters

30 Day Regulatory Window Captures Heart Attacks, Strokes, and Blood Clots

Peter A. McCullough, MD, MPH™

I have served on or chaired two dozen data safety monitoring boards for randomized trials of novel experimental drugs or devices. I can tell you first hand that for COVID-19 vaccines, a 30 day regulatory window after injection is fair game for attribution of health events to the product when the adverse events of interest are known to be caused by the mRNA induced Wuhan Spike protein.

Jabagi et al, NEJM, reported from the French National Health Data System linked to the national COVID-19 vaccination database disclosing cardiovascular events after mRNA BA4/BA5 bivalent boosters. All persons who were 50 years of age or older and who had received a booster dose between October 6 and November 9, 2022, were included in the study. The composite of ischemic/hemorrhagic stroke, myocardial infarction, or pulmonary occurred in 335 unfortunate individuals. The authors make the mistake of dividing by the cases by the entire number vaccinated and comparing rates to monovalent boosters. Neither of these operations are valid since there is incomplete capture of events and comparison was not made to a placebo or control group.

(See link for article)

Both Malhotra and McCullough are cardiologists. It would behoove us to listen closely.

Despite these frightening developments (among many others) the Biden Admin just announced a $5 Billion public-private partnership on Next Gen COVID “vaccines,” even though Biden just signed a bill formally ending the COVID emergency.

http://  Approx. 8 Min

$5Billion Big Pharma Partnership

I’m sure they’ll get it right this time…..

For more:

Category:

Activism, vaccines, Viruses

FDA Draft Guidance Addresses Clinical Development of Drugs to Treat Early Lyme – Parts 1 & 2

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/

FDA draft guidance addresses clinical development of drugs to treat early Lyme disease

Carl Tuttle

Hudson, NH, United States

APR 2, 2023 — 

The FDA is drafting guidance for Lyme Disease Drug Development. Not surprisingly they have completely mischaracterized the disease and target patient population. It looks like we have an important opportunity to educate them before sick patients aren’t included in the cohorts eligible to receive treatment. Similar to the vaccine, working with the wrong population will make treatments look effective even if they are not. It also prevents drug developers from being able to address what the real disease is and does. April 3 at 11:59 pm is the deadline for comments. Please consider commenting and/or sharing with others.

Announcement:
https://www.raps.org/news-and-articles/news-articles/2023/2/fda-draft-guidance-addresses-clinical-development

Draft Guidance: 
https://www.fda.gov/media/164949/download

Comment Here
https://www.regulations.gov/commenton/FDA-2022-D-2315-0002

Carl Tuttle’s Submitted comment…

Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment; Guidance for Industry – DRAFT GUIDANCE

Office of Communications,
Division of Drug Information Center for Drug Evaluation and Research
Food and Drug Administration

Focusing on the early stage of Lyme disease with bulls-eye rash is the root cause of this failed Public Health Response. Less than 50% of Lyme patients developed that rash as recorded by Epidemiologists in the State of Maine.

2011,  42% developed the rash:  http://www.maine.gov/dhhs/mecdc/infectious-disease/epi/vector-borne/lyme/documents/2011-lyme-legislature.pdf

2012,  49% developed the rash:  http://www.maine.gov/dhhs/mecdc/infectious-disease/epi/vector-borne/lyme/documents/2012-lyme-legislature.pdf

2013,  51% developed the rash:  http://www.maine.gov/dhhs/mecdc/infectious-disease/epi/vector-borne/lyme/documents/2013-lyme-legislature.pdf

2014,  57% developed the rash:  http://www.maine.gov/dhhs/mecdc/infectious-disease/epi/vector-borne/lyme/documents/2014-lyme-legislature.pdf

Lyme was pigeonholed into the category of “Hard to Catch and Easily Treated” through an elaborate scheme focusing on the acute stage of disease with bulls-eye rash and early treatment while avoiding the horribly disabled Lyme patient population. [i] The Centers for Disease Control financed the dishonest science using taxpayer dollars [ii] under grant# RO1 CK 000152 [iii] which has misguided a nation of intelligent physicians through the deliberate suppression of evidence of persistent Borrelia infection after aggressive antibiotic treatment. [iv]

This well-orchestrated scheme has misclassified Lyme as a low-risk and non-urgent health threat which actually belongs in the same health threat category as AIDS, Zika, cancer etc. and requires a Manhattan Project to understand how the infection it disables its victim just like untreated strep throat leads to rheumatic fever causing irreversible heart damage, untreated HIV leads to AIDS with substantial disability and death and untreated syphilis leads to progressive disability and dementia. Patients with a prolonged exposure to the Lyme disease pathogen are almost always incapacitated. Many these patients are often diagnosed with the chronic diseases of our time with no known etiology as exposed in the “Under our Skin” extended trailer:

Under Our Skin – Extended Trailer (please watch)
https://www.youtube.com/watch?v=sxWgS0XLVqw

There are no guidelines for treating the late stage disabled Lyme patient (who ends up bedridden or in a wheelchair) listed in the recently revised IDSA Lyme Treatment Guideline because that class of patient has been deliberately avoided at all costs so as not to expose the truth while keeping the current paradigm intact.

In fact, the IDSA does not want clinicians to rule out Lyme in patients who have been diagnosed with the chronic diseases of our time:

June article in Medscape by past IDSA president Paul Auwaerter

A Quick Tour of the New Lyme Disease Guideline
https://www.medscape.com/viewarticle/951589

Paul G. Auwaerter, MD

June 14, 2021

Excerpt:

“Of importance, the guideline goes out of its way to cite the lack of evidence for performing Lyme disease tests, specifically routine testing in cases where there’s no evidence or link to Lyme disease. Examples include someone who is asymptomatic after a tick bite, even when they have a neurologic condition such as amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, dementia, or any kind of new-onset seizures or psychiatric illness. In children, behavioral and developmental disorders don’t warrant assessing a Lyme disease serology.”

____________________________________

I sent an email to Dr. Auwaerter pointing out that a recent study identified tick-borne infections in nine out of ten institutionalized adolescents: [v] [vi]

Study detects tick-borne illness in teens hospitalized for depression
https://www.lymedisease.org/hospitalized-teens-lyme-depression/

-Ten patients were diagnosed with DSM-5 Major Depressive Disorder, seven were additionally diagnosed with Generalized Anxiety Disorder, and three had made serious suicide attempts.

-Ten adolescents picked at random with mental illness severe enough that they required institutionalization— nine of them had evidence of tick-borne infections and nine had evidence of autoimmune encephalitis.

__________________________________________

Instead of playing along with the dishonesty by avoiding the truth/evidence that Lyme is a disabling disease, our public health officials responsible for this travesty should be thoroughly investigated and held accountable to ensure this atrocity will never repeat itself.

Summary:

Stop focusing on the early stage of Lyme disease with bulls-eye rash and find a cure for all stages of the disease. Include patients in this study who are horribly disabled by an infection capable of destroying lives, ending careers while leaving its victims in financial ruin as reported by the Lyme patient population for the past thirty years!

Respectfully submitted,

Carl Tuttle
Hudson, NH

References (please read them!)

  1. NEWS: Former patient who testified as a child about Lyme disease recalls encounter with Sen. Ted Kennedy 
    https://www.lymedisease.org/186/
    Evan White testified from his wheelchair in 1993 at Senator Ted Kennedy’s Hearing, Washington DC
    Excerpt: 
    “No one could hear or feel the moment of that child and not be moved,” Kennedy explained to the [Boston] Globe at the time. Anyone who wasn’t moved, he said, “hasn’t got a heart.”
  2. Feb 4, 2020 complaint regarding the misuse of taxpayer dollars  https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/25876147
  3. Subjective Symptoms after Treatment of Lyme Disease  https://reporter.nih.gov/search/14E9C8084784C1D47598B8961CAA4A01A2FFCEB861BF/projects?shared=true&legacy=1
  4. Lyme borreliosis: diagnosis and management  https://www.bmj.com/content/369/bmj.m1041/rr-1
  5. A Quick Tour of the New (IDSA) Lyme Disease Guideline  https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/29231613
  6. A Quick Tour of the New (IDSA) Lyme Disease Guideline #2  https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/29263852

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/3146

FDA draft guidance addresses clinical development of drugs to treat early Lyme disease Part 2

Carl Tuttle

Hudson, NH, United States
APR 4, 2023 — 

As a follow-up to my previous comment to the FDA regarding “drugs to treat early Lyme disease,” please take a moment to read the comment below registered by the team at TruthCures. We all agree that early Lyme with bulls-eye rash does not represent the entire patient population and has been used by the IDSA and CDC to control and manipulate the narrative in order to support the vaccine business model of patent royalties and pharmaceutical profits. Chronic Lyme disease DOES NOT fit that model!

Comment from TruthCures:

Response to Docket No. FDA-2022-D-2315 for “Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment”

As a patient advocacy organization working to bring valid diagnostics and effective treatments to people with Lyme disease (LD), TruthCures supports innovation in therapeutics and properly designed trials to ascertain their efficacy. Thank you for the opportunity to comment on this guidance.

Trial Population

The trial population suggested in this guidance consists of “…subjects with early localized (i.e., a single EM lesion) or early disseminated (i.e., multiple EM lesions) disease, who reside in or traveled to a Lyme-endemic area.” Limiting any therapeutic trial to only cases presenting with erythema migrans (EM) rash will restrict the trial population to a minority cohort that may not be representative of the broader patient population.

The Centers for Disease Control and Prevention (CDC) estimates 476,000 LD cases in the United States each year (Kugeler et al 2021). However, in 2020, only 44,937 LD cases were reportable as “confirmed” or “probable” based on CDC surveillance criteria (CDC 2020). For diagnosis of a reportable case of early LD, CDC surveillance criteria require either a physician-diagnosed EM rash or laboratory confirmation of infection by methods that may include culture, nucleic acid amplification, immunohistochemical assay on biopsy or autopsy tissues, or two-tier serological testing (CDC 2022).

In clinical practice, diagnostic criteria set forth by the Infectious Diseases Society of America are virtually indistinguishable from the CDC surveillance criteria (IDSA 2006). With both sets of criteria requiring physician-diagnosed EM rash and/or laboratory confirmation, it stands to reason that the vast majority of EM rashes are being counted in the reported surveillance cases. In the public discourse, the absence of such context promotes a misconception that the prevalence of EM rash is based on the total of LD cases rather than the reported cases, creating an inflated perception of the prevalence of EM rash with Lyme.

A simple mathematical analysis illustrates the staggering difference between the narrative and reality.

● The literature frequently cites an EM rate of 60% – 80% (IDSA 2006, Steere et al 1998, CDC 2021). For calculation purposes we will use 70%.
● The public incorrectly believes EM cases are calculated as 70% of 476,000, or 333,200.
● Published studies state the EM rate is calculated based on reported LD cases—those meeting the IDSA and/or CDC surveillance reporting criteria (Kugeler 2020, Smith et al 2002, Seltzer et al 2000). For 2020, EM cases
would be 70% of 44,937, or 31,456.
● Therefore, the effective rate of EM is about 6.6% (31,456 out of 476,000).

It should not have to be said that results of a treatment trial limited to 6.6 percent of patients would not necessarily extrapolate to the entire Lyme disease patient population—particularly when it is unclear why the minority exhibit a distinct cutaneous manifestation. Indeed, Kannangara and Patel note, “EM seems to correlate more with the arthropod than the associated pathogen. The common belief is that EM is caused by B. burgdorferi. The presence of an organism in a skin biopsy culture or PCR does not necessarily mean that it is the cause of EM.” (Kannegara 2020)

Efficacy Endpoints

From the guidance document:

“Clinical success should be defined as resolution of EM and continued absence of objective manifestations of Lyme disease without need for additional antibacterial treatment for Lyme disease.”

“Clinical failure should be defined as the presence of unresolving or recurrent EM, objective manifestations of Lyme disease, or the need for additional antibacterial treatment for Lyme disease.”

Remission of cutaneous symptoms has not been determined to correlate with disease cure (IDSA 2006, Steere et al 2016, Feder et al 2011), and, as is common knowledge, there is no diagnostic method available to determine either cure or disease stage.

It is commonly reported in the literature that EM rash resolves on its own in three to four weeks (Kardos 2002, Feder 1993, Nadelman 1997, Wheaton 2012, Dressler 1999). Therefore, the definition of clinical success (“resolution of EM”) could not necessarily be attributed to the treatment. Likewise, clinical failure could not be attributed to lack of efficacy if efficacy itself is not ascertainable. Lacking the ability to determine success or failure based on EM resolution, an alternative would be to run a separate trial to determine whether the therapeutic has any effect on time to resolution of EM.

Additionally, there is the possibility that patients present with EM rash and no other symptoms. In these cases, without the ability to correlate disease cure with resolution of EM, there is no other way to gauge efficacy of a therapeutic.

Conclusion

Using only patients who present with EM rash for a therapeutic efficacy trial would exclude 93% of patients, with no insight into the factors (e.g. genetic or comorbidities) that cause certain people to develop the rash. Resolution of EM rash is not an indication that Lyme disease has been cured or spirochetes eradicated.

TruthCures’ mission is to enable Lyme disease victims to obtain a valid diagnosis and effective medical care. While we support endeavors to discover novel treatments, we believe valid diagnostics must come first. As long as Lyme disease cannot be accurately and consistently diagnosed, therapeutics cannot be developed for the right patients using the right efficacy endpoints.

Following a complaint to FDA’s Office of Criminal Investigation, TruthCures presented to investigators in-person, in October 2021. We provided evidence that Lyme disease diagnostics have been predicated on improperly cleared devices going all the way back to 1995. The investigators agreed with our diagnostic device regulatory expert’s assessment of those devices. We suggest focusing FDA’s Lyme disease efforts on completing that investigation so valid tests can be developed and marketed rather than daisy-chaining off a manipulated standard.

It is well known that seronegative Lyme presents one of the biggest challenges in validating diagnostics. The gap between reported surveillance cases (44,937 in 2020) and CDC’s estimated annual cases (476,000) indicates more than 400,000 patients per year may be falling through the cracks due to the inability of serology to properly diagnose them. Many of these victims lose everything—family, friends, job, home, retirement savings, education, and more—due to chronic illness and the stigma of having a “contested” disease. We respectfully request you take a step back and reassess whether it makes sense to produce any guidance that effectively leaves those patients out of the equation once again.

REFERENCES

  • Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS; Hinckley AF. Estimating the
    Frequency of Lyme Disease Diagnoses, United States, 2010-2018. Emerg Infect Dis
    2021;27: 616-619.
  • Centers for Disease Control and Prevention. “2020 Lyme Disease Data: Provisional Data.” Centers for Disease Control and Prevention, 2020,https://www.cdc.gov/lyme/datasurveillance/provisional-lyme-cases.htm
  • Centers for Disease Control and Prevention. “2022 Lyme Disease Surveillance Case Definition.” Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 1 Jan. 2022, www.cdc.gov/lyme/resources/2022-surveillance-case-definition.html
  • Infectious Diseases Society of America. “The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America.” Clinical Infectious Diseases, vol. 43, no. 9, 1 Nov. 2006, pp. 1089-1134.
  • Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med. 1998;339(4):209-215. doi: 10.1056/nejm199807233390401.
  • Centers for Disease Control and Prevention. “Signs and Symptoms of Untreated Lyme Disease.” Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2021. https://www.cdc.gov/lyme/signs_symptoms/index.html
  • Smith, R. P., Schoen, R. T., Rahn, D. W., Sikand, V. K., Nowakowski, J., Parenti, D. L., …& Steere, A. C. (2002). Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Annals of Internal Medicine, 136(6), 421-428.
  • Seltzer, E. G., Gerber, M. A., Cartter, M. L., Freudigman, K., & Shapiro, E. D. (2000). Long-term outcomes of persons with Lyme disease. JAMA, 283(5), 609-616.
  • Kannangara, Don Walter and Patel, Pritiben. “Report of Non-Lyme, Erythema Migrans Rashes from New Jersey with a Review of Possible Role of Tick Salivary Toxins.” Journal of Medical Entomology, vol. 57, no. 1, 2020, pp. 28-34.
  • Kardos, Marton, et al. “Erythema migrans resolving without antibiotic treatment in a patient with confirmed Lyme disease.” Journal of the American Academy of Dermatology, vol. 47, no. 3, 2002, pp. S204-S207. doi: 10.1067/mjd.2002.123625.
  • Feder, Henry M. Jr., et al. “A Critical Appraisal of ‘Chronic Lyme Disease’.” New England Journal of Medicine, vol. 328, no. 7, 1993, pp. 921-924. doi: 10.1056/NEJM199304013281311.
  • Nadelman, Robert B., et al. “Does this Patient Have Lyme Disease?” Annals of Internal Medicine, vol. 127, no. 12, 1997, pp. 1109-1113. doi: 10.7326/0003-4819-127-12-199712150-00005.
  • Wheaton, Anne J., et al. “Lyme Disease in Primary Care Practice.” Journal of the American Board of Family Medicine, vol. 25, no. 6, 2012, pp. 817-820. doi: 10.3122/jabfm.2012.06.120055.
  • Dressler, Franz, et al. “The Clinical Spectrum and Treatment of Early Lyme Borreliosis in Patients with Skin Manifestations Only.” Journal of the American Academy of Dermatology, vol. 41, no. 3 Pt 1, 1999, pp. 1-7. doi: 10.1016/S0190-9622(99)70134-7.
  • Steere, A. C., Strle, F., Wormser, G. P., Hu, L. T., Branda, J. A., Hovius, J. W., … & Stanek, G. (2016). Lyme borreliosis. Nature Reviews Disease Primers, 2, 16090.
  • Feder, H. M., Johnson, B. J., O’connell, S., Shapiro, E. D., Steere, A. C., Wormser, G.P., & Ad Hoc International Lyme Disease Group. (2007). A critical appraisal of “chronic Lyme disease”. New England Journal of Medicine, 357(14), 1422-1430.

Category:

Activism, Lyme, Testing

Mistakes Were Not Made: “Don’t Let Them Get Away With It”

http://  Approx. 4 Min

Mistakes Were NOT Made: An Anthem for Justice (Video)

“Don’t Let Them Get Away With It”

Dr. Tess Lawrie‘s potent message for an awakening public.
Go here for the powerful video as Youtube has shown its true colors once again by censoring this message.
Peter A. McCullough, MD, MPH™

By JOHN LEAKE

There are notable moments in history when the overlords of this world go too far in their exercise of power and commit a crime that is a glaring expression of their arrogance. Such a crime is memorialized and becomes symbolic of their tyranny. Decent people are shocked by the spectacle of it and conclude that the overlords no longer have any legitimate claim to rule.

I woke up this morning thinking about the complicated ideas of justice, redemption, and forgiveness. The final concept, forgiveness, can only happen after those who have committed a crime are publicly identified and held accountable for it. Source  (See link for article)

Also see Margaret Anna Alice’s article, as this is the information that Dr. Lawrie shares in the powerful video above that was derived from a poem Anna Alice wrote.  The main point: COVID and all that followed was not a mistake or a blunder.  The entire poem is corroborated with sources so if you doubt the information, check it out for yourself.

For more:

It’s all planned and all related.  Every Single Bit Of It

Brought to you by Pfizer.

Category:

Activism, vaccines, Viruses

FDA Director Issues Shocking Threat If You Don’t Take New Injection

http://  Approx. 8 Min

FDA Director Issues Shocking Threat if You Don’t Take New Injection

4/10/23

Dr. Suneel Dhand discusses FDA Director Dr. Peter Mark’s statement that while “vaccine” mandates are not the way to go, the shot is for those who “want to save their lives,” insinuating that those who don’t take the jab don’t want to save their lives.  Dhand states that this shockingly absurd statement is indicative of the past years with COVID.  Marks freely admits that despite attempting for 10 years to produce a “vaccine” to prevent the flu, it hasn’t happened yet, and he doesn’t expect the next for COVID shot to be “too different” from what’s currently available.

  • The FDA is supposed to be a regulatory agency and has no business pushing medical therapeutics and formulating policy
  • The FDA has no evidence to support the assertion that the COVID injections will reduce hospitalization or save your life
  • This typifies the sheer arrogance of our public health ‘authorities’ and reveals they have learned nothing from COVID
  • Rather than simply reflecting upon their own mismanagement of COVID for the erosion in confidence for both public health and “vaccines,”  they will continue to blame others for ‘misinformation’
  • There are 88 bills in state legislatures to roll back or outlaw any sort of “vaccine” mandate.  Public health “vaccine” pushers simply can not fathom this and continue to falsely state that there are too many people dying of COVID – again insinuating that the COVID injections somehow stop this, which they don’t
  • Interestingly, Penny Heaton, MD, Global Therapeutic Area Head for Vaccines at J&J, is interested in moving beyond lipid nanoparticles that may be “potentially less reactogenic, potentially more immunogenic, potentially actually direct[ing] the exact immune response we want.”  This statement admits the COVID shots are reactogenic, not immunogenic, and are not giving the correct immune response.

Category:

Activism, vaccines, Viruses